Drug intelligence / Profile preview

XG2002

Development stage: Unknown
Lead developer: Xgene Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

XG2002 is an orally bioavailable small molecule modulator of the Transient Receptor Potential Melastatin 8 (TRPM8) channel, developed by Xgene Pharmaceutical Group. TRPM8 is a cold-sensing non-selective cation channel primarily expressed in sensory neurons and is a key mediator in the detection of environmental cold and the development of cold allodynia. XG2002 is designed to target TRPM8 to treat various chronic pain conditions, with a specific focus on metastatic bone pain. The drug candidate has successfully completed a Phase 1 clinical trial in Australia, which assessed its safety, tolerability, and pharmacokinetics in healthy subjects.

Targets

TRPM8 (Transient receptor potential cation channel subfamily M member 8)

Beyond the preview

Go deeper on XG2002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XG2002.

Explore the full profile